Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Transkaryotic, Aventis Pharmaceuticals Inc. renal, hematology news

A trial date of May 15 has

Read the full 77 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE